PharmaVentures appoints senior director

Paul Phull will develop corporate advisory business

PharmaVentures, based in Oxford, UK, has hired Paul Phull as senior director to develop its corporate advisory business.

PharmaVentures is an international corporate advisory firm supporting its clients’ growth ambitions through licensing, joint ventures and M&A in the healthcare industry. The company works for a variety of clients from start-ups to global pharmaceutical corporations, their advisers, investment companies and government bodies.

Phull joins the company from Sinclair Pharma, a specialist pharmaceutical company in the UK, where he was responsible for the development of the international business. He has significant deal making and corporate transaction experience with a broad range of companies in Europe, US, Japan, India and Asia in a number of therapeutic areas.

You may also like

Regulatory

MoonLake Immunotherapeutics faces Securities Class Action after disastrous Phase III trial results

The announcement about the trial results for the product candidate sonelokimab, a highly anticipated treatment for patients with skin disease, saw MoonLake investors' shares fall by about 90%, prompting an investigation into whether or not they were misled
Finance

Novo Nordisk acquires rights to Omeros’ MASP-3 inhibitor zaltenibart in $2.1bn deal

The agreement grants Novo Nordisk exclusive global rights to develop and commercialise the clinical-stage antibody for rare blood and kidney disorders, strengthening its Rare Disease portfolio
Finance

Kailera Therapeutics secures $600m in Series B financing to advance next-generation obesity therapies

The funding will support the advancement of Kailera’s obesity portfolio, including a global Phase III clinical programme of Kailera’s lead candidate KAI-9531, an injectable dual GLP-1/GIP receptor agonist with potentially best-in-category weight loss
Finance

LTS expands CDMO footprint with acquisition of Renaissance Lakewood

LTS Lohmann Therapie-Systeme has agreed to acquire US-based CDMO Renaissance Lakewood, strengthening its position in nasal spray and sterile dosage form manufacturing and broadening its global drug delivery capabilities
Finance

Nanoform collaborates with A.forall and IMGA to outlicence Nanoencorafenib

Nanoform will establish a new company, BRAFMed, to progress the clinical development and future outlicensing of the patient-centric nanoformulation of encorafenib
Manufacturing

Gerresheimer adjusts 2025 guidance amid slower market growth

Transformation program launched to boost performance and free cash flow
Manufacturing

AstraZeneca strikes deal with US government to cut drug prices and boost domestic manufacturing

AstraZeneca has reached an agreement with the Trump administration to lower medicine costs, pledging $50bn in US manufacturing and R&D investment, whilst safeguarding the nation’s biopharma innovation leadership
Subscribe now